Skip to main content

Table 3 Univariate and multivariate analysis of risk factors for locoregional recurrence (LRR), overall survival (OS) and disease-free survival (DFS) in entire cohort

From: Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

Variables

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

5-year LRR % (events)

P

HR (95%CI)

P

5-year OS % (events)

P

HR (95%CI)

P

5-year DFS % (events)

P

HR (95%CI)

P

Treatment center

 Cohort 1

6.1 (152)

 

1.00

 

93.9 (148)

 

1.00

 

85.5 (367)

 

1.00

 

 Cohort 2

7.5 (97)

.229

0.94 (0.73–1.23)

.675

91.6 (105)

.012

1.08 (0.86–1.37)

.491

83.5 (216)

.672

0.87 (0.73–1.04)

.122

Year

 1999–2008

7.6 (142)

 

1.00

 

91.5 (158)

 

1.00

 

82.8 (328)

 

1.00

 

 2009–2014

5.6 (107)

.033

1.00 (0.76–1.33)

.980

94.9 (95)

< .001

0.79 (0.61–1.03)

.079

86.7 (255)

< .001

0.88 (0.74–1.06)

.187

Age (years)

 ≤ 40

9.6 (65)

 

1.00

 

92.6 (52)

 

1.00

 

81.0 (134)

 

1.00

 

 > 40

5.9 (184)

.002

0.61 (0.48–1.80)

< .001

93.2 (201)

.184

0.77 (0.61–0.97)

.026

85.8 (449)

.013

0.74 (0.62–0.87)

< .001

T stage

 T1

3.9 (70)

 

1.00

 

94.9 (87)

 

1.00

 

89.6 (188)

 

1.00

 

 T2

9.1 (179)

< .001

1.87 (1.47–2.38)

< .001

91.4 (166)

< .001

1.58 (1.28–1.93)

< .001

80.6 (396)

< .001

1.58 (1.36–1.83)

< .001

SLNB

 No

7.6 (240)

 

1.00

 

92.9 (250)

 

1.00

 

84.7 (568)

 

1.00

 

 Yes

6.2 (9)

.635

2.24 (1.23–4.09)

.008

98.1 (3)

.046

0.83 (0.36–1.92)

.670

90.1 (15)

.103

1.11 (0.69–1.80)

.659

No. of ALND

 ≤ 19

7.2 (73)

 

1.00

 

92.3 (183)

 

1.00

 

83.4 (411)

 

1.00

 

 > 19

5.5 (76)

.200

0.85 (0.66–1.08)

.186

94.6 (70)

.012

0.78 (0.63–0.97)

.029

87.7 (171)

.008

0.82 (0.70–0.96)

.013

No. of positive nodes

 1

5.8 (112)

 

1.00

 

94.0 (115)

 

1.00

 

85.8 (281)

 

1.00

 

 2

7.1 (80)

 

1.53 (1.19–1.97)

.001

92.9 (77)

 

1.21 (0.97–1.51)

.084

84.5 (179)

 

1.18 (1.01–1.39)

.041

 3

8.0 (57)

.002

1.77 (1.33–2.36)

< .001

90.8 (61)

.049

1.43 (1.12–1.84)

.004

82.9 (123)

.006

1.32 (1.09–1.58)

.004

Lymphovascular invasion

 No

6.1 (189)

 

1.00

 

93.5 (195)

 

1.00

 

85.8 (447)

 

1.00

 

 Yes

8,7 (37)

 

1.27 (0.92–1.75)

.146

91.5 (32)

 

1.03 (0.75–1.42)

.851

80.7 (82)

 

1.16 (0.93–1.44)

.196

 Unknown

8.5 (23)

.053

0.76 (0.48–1.21)

.254

90.4 (26)

.100

0.92 (0.64–1.33)

.655

80.3 (54)

.056

0.92 (0.69–1.24)

.590

Histological grade

 I- II

4.8 (103)

 

1.00

 

94.6 (110)

 

1.00

 

87.8 (266)

 

1.00

 

 III

10.3 (83)

 

1.41 (1.08–1.84)

.011

91.4 (76)

 

1.35 (1.06–1.71)

.014

81.6 (172)

 

1.20 (1.01–1.43)

.042

 Unknown

8.6 (63)

< .001

1.21 (0.87–1.69)

.259

90.7 (67)

< .001

1.03 (0.77–1.37)

.851

80.5 (145)

< .001

1.10 (0.89–1.35)

.389

Surgery type

 MRM

7.0 (240)

 

1.00

 

92.7 (241)

 

1.00

 

84.0 (557)

 

1.00

 

 BCS

2.3 (9)

.001

1.00 (0.54–1.86)

.996

96.5 (12)

.001

1.19 (0.72–1.99)

.495

92.9 (27)

< .001

0.79 (0.55–1.14)

.204

Radiotherapy

 No

7.6 (209)

 

1.00

 

92.5 (202)

 

1.00

 

84.1 (445)

 

1.00

 

 Yes

3.8 (40)

< .001

0.42 (0.29–0.59)

< .001

94.7 (51)

< .001

0.62 (0.46–0.83)

.001

86.8 (138)

.001

0.77 (0.64–0.94)

.009

Chemotherapy

 No

4.7 (10)

 

1.00

 

89.1 (23)

 

1.00

 

83.9 (35)

 

1.00

 

 Yes

6.7 (239)

 

0.96 (0.44–2.09)

.922

93.3 (229)

 

0.40 (0.22–0.71)

.002

84.9 (546)

 

0.52 (0.33–0.80)

.003

 Unknown

0 (0)

.546

0.58 (0.07–4.55)

.606

94.4 (1)

< .001

0.23 (0.03–1.69)

.149

88.9 (2)

.003

0.28 (0.07–1.17)

.081

Chemotherapeutic drug

 Taxane-based

6.1 (142)

 

1.00

 

94.5 (123)

 

1.00

 

86.4 (324)

 

1.00

 

 Others

8.6 (88)

 

1.42 (1.08–1.87)

.011

90.6 (95)

 

1.22 (0.96–1.56)

.103

80.7 (201)

 

1.20 (1.01–1.44)

.041

 Unknown

4.5 (19)

.005

0.87 (0.48–1.57)

.614

91.4 (35)

< .001

1.11 (0.66–1.88)

.692

86.3 (58)

< .001

0.89 (0.61–1.30)

.551

Hormone receptor & Hormonal therapy

 negative & no

13.0 (106)

 

1.00

 

85.9 (108)

 

1.00

 

73.2 (223)

 

1.00

 

 positive & yes

4.6 (118)

 

0.52 (0.40–0.66)

< .001

95.6 (108)

 

0.44 (0.35–0.55)

< .001

89.0 (286)

 

0.55 (0.47–0.65)

< .001

 positive & no

6.5 (18)

 

0.49 (0.30–0.78)

.003

90.5 (26)

 

0.78 (0.56–1.09)

.153

81.7 (53)

 

0.67 (0.50–0.89)

.005

 Unknown

6.1 ()

< .001

0.79 (0.43–1.47)

.465

90.9 (11)

< .001

0.59 (0.34–1.02)

.060

82.4 (21)

< .001

0.74 (0.50–1.11)

.144

HER2 & Target therapy

 negative & no

5.7 (145)

 

1.00

 

94.1 (147)

 

1.00

 

86.5 (352)

 

1.00

 

 positive & yes

4.9 (10)

 

0.84 (0.46–1.53)

.578

98.6 (3)

 

0.44 (0.20–0.93)

.032

90.2 (19)

 

0.63 (0.41–0.98)

.038

 positive & no

12.0 (63)

 

1.55 (1.18–2.04)

.002

87.7 (62)

 

1.35 (1.05–1.73)

.017

75.7 (133)

 

1.33 (1.10–1.60)

.003

 Unknown

6.1 (31)

< .001

1.07 (0.77–1.50)

.677

91.4 (41)

< .001

1.13 (0.86–1.49)

.374

84.3 (79)

< .001

1.03 (0.83–1.27)

.788

  1. Abbreviations: HR Hazard ratio, CI Confidence interval, SLNB Sentinel lymph node biopsy, ALND Axillary lymph node dissection, HER2 Human epidermal growth factor receptor 2